Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers.

导出 LinkOut

翻译打印收藏纠错

第一作者： Christopher L,Carroll

第一单位： Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.

作者： Christopher L,Carroll ^[1] ; Michael G,Johnson ^[2] ; Yanbing,Ding ^[3] ; Zhijun,Kang ^[1] ; R S K,Vijayan ^[1] ; Jennifer P,Bardenhagen ^[1] ; Cheng,Fang ^[3] ; David,Lapointe ^[2] ; Meng,Li ^[3] ; Chiu-Yi,Liu ^[4] ; Xiaobing,Lv ^[3] ; XiaoYan,Ma ^[4] ; Jihai,Pang ^[1] ; Hannah E,Shepard ^[1] ; Catalina,Suarez ^[1] ; Anne Ju,Yau ^[1] ; Christopher C,Williams ^[1] ; Qi,Wu ^[1] ; Robert A,Heald ^[5] ; Helen M R,Robinson ^[5] ; Graeme C M,Smith ^[5] ; Jason B,Cross ^[1] ; Mary K Geck,Do ^[1] ; Yongying,Jiang ^[1] ; Sarah,Lively ^[2] ; Timothy A,Yap ^[6] ; Virginia,Giuliani ^[4] ; Timothy,Heffernan ^[4] ; Philip,Jones ^[1] ; M Emilia,Di Francesco ^[1]

作者单位： Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States. ^[1] ChemPartner Corporation, South San Francisco, California 94080, United States. ^[2] ChemPartner Corporation, Shanghai 201203, China. ^[3] Translational Research to AdvanCe Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States. ^[4] Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge CB223FH, U.K. ^[5] Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.;Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.;Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States. ^[6]